 CAMBRIDGE, Mass., April 27, 2022 GLOBE NEWSWIRE -- Surface Oncology Nasdaq: SURF, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will share a clinical update on SRF388 in an oral presentation at the American Society of Clinical Oncology ASCO 2022 Annual Meeting, to be held June 3-7, 2022 in Chicago, Il. 